Table 1 Course of treatment with FM2, with clinical outcomes
From: The use of medical cannabis in pediatric palliative care: a case series
Patient | Starting/maximal dose (mg/kg/day) | Effective dose (mg/kg/day) | Dosage changes (n) | Titration changes (n) | Daily frequency of seizures (beginning/best result; features) | % of days free from seizures (beginning/best result) | % of days free from pain (beginning/best result) | Adverse events with dose of FM2 at occurrence |
|---|---|---|---|---|---|---|---|---|
1 | 0.11/059 | 0.55 | 7 | 10 | 0.11/0.26; tonic–clonic | 89/89 | 100/100 | No |
2 | 0.11/0.52 | 0.38 | 5 | 9 | 8/2.31 | 0/0 | 3/82.8 | Drowsiness with 0.52 mg/kg/day |
3 | 0.1/0.48 | 0.48 | 4 | 3 | 3.57/2 | 0 / 33 | 28/100 | Euphoria with 0.1 mg/kg/day |
4 | 0.1/0.22 | 0.22 | 4 | 4 | 0.79/1 | 57/73 | NA | Drowsiness: resolution with schedule change from 0.4 ml × 3 to 0.3 + 0.4 + 0.8 ml each day |
5 | 0.12 | 0.2 | 4 | 2 | 5/3; absence and tonic–clonic | 0/NA | 25/58 | Drowsiness: remission with schedule change from 0.65 ml three-times/day to 0.5 + 0.5 + 0.9 ml/day |
6 | 0.71/1.2 | 0.44 | 3 | 6 | 0.23/0.14 | NA | NA | Irritability with 1.2 mg/kg/day: dose reduction to 0.85 mg/kg/day Euphoria with 0.6 mg/kg/day: spontaneous resolution |